Last update 07 Nov 2024

LMY-920

Overview

Basic Info

Drug Type
Autologous CAR-T
Synonyms
LMY 920, LMY-920
Target
BAFF-R x BCMA x TACI
Mechanism
BAFF-R inhibitors(B-cell activating factor receptor inhibitors), BCMA inhibitors(B-cell maturation protein inhibitors), TACI modulators(Tumor necrosis factor receptor superfamily member 13B modulators)
Therapeutic Areas
NeoplasmsImmune System DiseasesCardiovascular Diseases+ [3]
Active Indication
Systemic Lupus ErythematosusPlasma cell myeloma refractoryRelapse multiple myeloma+ [3]
Inactive Indication-
Originator Organization
Luminary Therapeutics, Inc.Luminary Therapeutics, Inc.Startup
Active Organization
Luminary Therapeutics, Inc.Luminary Therapeutics, Inc.StartupThe Case Comprehensive Cancer CenterThe Case Comprehensive Cancer CenterCase Western Reserve UniversityCase Western Reserve University
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

3
Clinical Trials associated with LMY-920
NCT06340750 / Not yet recruitingPhase 1
A Phase I Study of BAFF CAR-T Cells (LMY-920) for Treatment of Systemic Lupus Erythematosus
NCT05546723 / RecruitingPhase 1
LUMT1A22, Phase 1 Study of BAFF CAR T Cells (LMY-920) for Treatment of Relapsed or Refractory Myeloma (LMY-920-002)
NCT05312801 / RecruitingPhase 1
LMY-920 for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
100 Clinical Results associated with LMY-920
Login to view more data
100 Translational Medicine associated with LMY-920
Login to view more data
100 Patents (Medical) associated with LMY-920
Login to view more data
100 Deals associated with LMY-920
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Systemic Lupus ErythematosusPhase 1
US
Luminary Therapeutics, Inc.Luminary Therapeutics, Inc.Startup
15 Jan 2025
Plasma cell myeloma refractoryPhase 1
US
Luminary Therapeutics, Inc.Luminary Therapeutics, Inc.Startup
13 Mar 2024
Plasma cell myeloma refractoryPhase 1
US
Case Western Reserve UniversityCase Western Reserve University
13 Mar 2024
Relapse multiple myelomaPhase 1
US
Luminary Therapeutics, Inc.Luminary Therapeutics, Inc.Startup
13 Mar 2024
Relapse multiple myelomaPhase 1
US
Case Western Reserve UniversityCase Western Reserve University
13 Mar 2024
B-Cell LymphomaPhase 1
US
The Case Comprehensive Cancer CenterThe Case Comprehensive Cancer Center
21 Nov 2023
Non-Hodgkin's lymphoma refractoryPhase 1
US
Luminary Therapeutics, Inc.Luminary Therapeutics, Inc.Startup
21 Nov 2023
Non-Hodgkin's lymphoma refractoryPhase 1
US
The Case Comprehensive Cancer CenterThe Case Comprehensive Cancer Center
21 Nov 2023
Recurrent Non-Hodgkin LymphomaPhase 1
US
The Case Comprehensive Cancer CenterThe Case Comprehensive Cancer Center
21 Nov 2023
Recurrent Non-Hodgkin LymphomaPhase 1
US
Luminary Therapeutics, Inc.Luminary Therapeutics, Inc.Startup
21 Nov 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free